An anti-tumor nano adjuvant is obtained by loading a drug on the vesicle formed by a reversibly cross-linked biodegradable polymer with an asymmetric membrane structure; the drug is an oligonucleotide activating an immune response; the vesicle formed by the degradable polymer is obtained by the self-assembly of a polymer followed by cross-linking; the molecular chain of the polymer includes a hydrophilic chain segment, a hydrophobic chain segment and positively charged molecules, successively connected; the hydrophobic chain segment is a polycarbonate chain segment and/or a polyester chain segment, which is compounded and loaded with a drug by electrostatic interaction; and the membrane is a polycarbonate chain segment and/or a polyester chain segment, which is reversibly cross-linked, biodegradable and has good biocompatibility, the dithiolane in the side chain thereof is similar to thioctic acid, a natural antioxidant in human body, and the shell thereof is based on PEG and targets cancer cells.

The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for the immunogen.

The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Embodiments of various aspects described herein are directed to methods, compositions, kits for detecting a target molecule in a sample. In particular, there is described herein a multivalent approach which provides an efficient method for detection of small molecules and screening of binding molecules (e.g., antibodies). The multivalent approach uses two or more small molecules in a domain that is attached to a substrate through a linking group. The multivalent domain is free to extend, e.g., into a solution, for presentation to a binding compound such as an antibody.

Compositions, reagents, formulations and methods to treat disease including autoimmune diseases and allergy are described. The compositions comprise an antigen causing immune intolerance, an immunosuppressant in a sustained release formulation. The methods, compositions, formulations and reagents to treat allergy also relate to applying the combination of allergen and immune activity enhancing agent in a sustained release formulation to a subject in need.

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule. The present invention also provides pharmaceutical compositions, particularly vaccines, comprising the inventive polymeric carrier cargo complex and the second nucleic acid molecule, as well as the use of the inventive polymeric carrier cargo complex and the second nucleic acid molecule for transfecting a cell, a tissue or an organism, as a medicament, for therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned herein. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and the second nucleic acid molecule, the inventive pharmaceutical composition and/or the inventive vaccine or any of its components in one or more parts of the kit.

Compositions, reagents, formulations and methods to treat disease including autoimmune diseases and allergy are described. The compositions and formulations comprise an antigen causing immune intolerance, an immunosuppressant and a viscosity enhancing agent or a thermal phase changing agent. The reagent is a polymer conjugate comprising an antigen causing immune intolerance and an immunosuppressant conjugated to a polymer.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.